Suppr超能文献

接受免疫检查点抑制剂治疗的肝癌患者脾脏体积动态变化与生存结局:一项回顾性分析

Spleen Volume Dynamics and Survival Outcomes in HCC Patients Undergoing Immune Checkpoint Inhibitors: A Retrospective Analysis.

作者信息

Fu Xiaona, Jiang Shanshan, Li Yi, Guo Yusheng, Gong Bingxin, Lou Jie, Li Yanlin, Wang Sichen, Sun Yuxin, Ren Yi, Chen Quan, Yang Lian

机构信息

Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.

Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, 430022, People's Republic of China.

出版信息

J Hepatocell Carcinoma. 2025 May 30;12:1069-1082. doi: 10.2147/JHC.S524483. eCollection 2025.

Abstract

PURPOSE

The spleen serves as an important immune organ which influences the anti-tumor immune response by modulating the immune microenvironment. This study investigated the prognostic impact of spleen volume (SV) on the survival in hepatocellular carcinoma (HCC) patients receiving immune checkpoint inhibitors (ICIs).

PATIENTS AND METHODS

This retrospective study included 224 HCC patients treated with ICIs, categorized into Higher and Lower SV groups by median SV and further into SV increased and Non-SV increased groups based on changes in SV at 3 months after ICIs. Kaplan-Meier curves and Cox regression models were used to evaluate the influence of SV and clinical indicators on progression-free survival (PFS) and overall survival (OS). Independent prognostic factors identified via multivariate analysis were incorporated into nomograms, with their accuracy assessed using concordance index (C-index), time-dependent receiver operating characteristic (ROC) and calibration curves. Restricted cubic spline (RCS) analysis was conducted to assess the relationship between baseline SV and survival.

RESULTS

The Higher SV and SV increased groups demonstrated shorter PFS and OS compared to the Lower SV and Non-SV increased groups, respectively. These results were consistent with different regimens in the Child A. The C-index of nomogram for PFS were 0.700 (0.678-0.721) and OS 0.733(0.709-0.757). The ROC and calibration curves confirmed robust discrimination and predictive accuracy of models. RCS analysis revealed a nonlinear association between baseline SV and survival risk, providing a more comprehensive overview of SV in relation to survival in HCC patients treated with ICIs.

CONCLUSION

The baseline SV and its relative change at three months after treatment are expected to become routine imaging makers for predicting survival in HCC patients receiving ICIs, which consequently contributes to their clinical management.

摘要

目的

脾脏是一个重要的免疫器官,通过调节免疫微环境影响抗肿瘤免疫反应。本研究调查了脾体积(SV)对接受免疫检查点抑制剂(ICI)治疗的肝细胞癌(HCC)患者生存的预后影响。

患者与方法

本回顾性研究纳入了224例接受ICI治疗的HCC患者,根据中位SV分为高SV组和低SV组,并根据ICI治疗后3个月SV的变化进一步分为SV增加组和非SV增加组。采用Kaplan-Meier曲线和Cox回归模型评估SV和临床指标对无进展生存期(PFS)和总生存期(OS)的影响。通过多变量分析确定的独立预后因素被纳入列线图,使用一致性指数(C指数)、时间依赖性受试者工作特征(ROC)和校准曲线评估其准确性。进行限制立方样条(RCS)分析以评估基线SV与生存之间的关系。

结果

高SV组和SV增加组的PFS和OS分别比低SV组和非SV增加组短。这些结果在Child A的不同治疗方案中是一致的。PFS列线图的C指数为0.700(0.678-0.721),OS为0.733(0.709-0.757)。ROC和校准曲线证实了模型具有强大的区分能力和预测准确性。RCS分析揭示了基线SV与生存风险之间的非线性关联,更全面地概述了SV与接受ICI治疗的HCC患者生存的关系。

结论

基线SV及其治疗后三个月的相对变化有望成为预测接受ICI治疗的HCC患者生存的常规影像学指标,从而有助于其临床管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae4e/12132512/95daecf2551e/JHC-12-1069-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验